[go: up one dir, main page]

MX2009011319A - Adenosina desaminasa recombinante estable. - Google Patents

Adenosina desaminasa recombinante estable.

Info

Publication number
MX2009011319A
MX2009011319A MX2009011319A MX2009011319A MX2009011319A MX 2009011319 A MX2009011319 A MX 2009011319A MX 2009011319 A MX2009011319 A MX 2009011319A MX 2009011319 A MX2009011319 A MX 2009011319A MX 2009011319 A MX2009011319 A MX 2009011319A
Authority
MX
Mexico
Prior art keywords
adenosine deaminase
recombinant adenosine
stable recombinant
disclosed
oxidizable
Prior art date
Application number
MX2009011319A
Other languages
English (en)
Inventor
David R Filpula
Stephen K Youngster
Original Assignee
Enzon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzon Pharmaceuticals Inc filed Critical Enzon Pharmaceuticals Inc
Publication of MX2009011319A publication Critical patent/MX2009011319A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04014—Deoxycytidine deaminase (3.5.4.14)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe una adenosina desaminasa recombinante de muteína que tiene cualquier residuo de cisteína oxidable reemplazado por un residuo aminoácido no oxidable; también se describen la adenosina desaminasa recombinante estabilizada, conjugados de polímero y métodos de tratamiento que utilizan la misma.
MX2009011319A 2007-04-20 2008-04-18 Adenosina desaminasa recombinante estable. MX2009011319A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91300907P 2007-04-20 2007-04-20
PCT/US2008/060805 WO2008131208A1 (en) 2007-04-20 2008-04-18 Stable recombinant adenosine deaminase

Publications (1)

Publication Number Publication Date
MX2009011319A true MX2009011319A (es) 2009-12-11

Family

ID=39875917

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011319A MX2009011319A (es) 2007-04-20 2008-04-18 Adenosina desaminasa recombinante estable.

Country Status (19)

Country Link
US (1) US8071741B2 (es)
EP (1) EP2147116B1 (es)
JP (1) JP5511653B2 (es)
KR (1) KR101499095B1 (es)
CN (1) CN101688244B (es)
AU (1) AU2008242748B2 (es)
BR (1) BRPI0810383B1 (es)
CA (1) CA2684750C (es)
DK (1) DK2147116T3 (es)
ES (1) ES2569940T3 (es)
HR (1) HRP20160482T1 (es)
HU (1) HUE027603T2 (es)
IL (1) IL201592A (es)
MX (1) MX2009011319A (es)
NZ (1) NZ580981A (es)
PL (1) PL2147116T3 (es)
SI (1) SI2147116T1 (es)
TW (1) TWI412591B (es)
WO (1) WO2008131208A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2147122T3 (pl) 2007-04-20 2015-05-29 Leadiant Biosciences Ltd Enzymatyczna terapia przeciwnowotworowa
IN2012DN04901A (es) * 2009-11-24 2015-09-25 Dow Agrosciences Llc
RU2573933C1 (ru) * 2014-08-21 2016-01-27 Дафот Энтерпрайсис Лимитед Пептид для лечения сахарного диабета 2-го типа и его осложнений
EP3207130B1 (en) * 2014-10-14 2019-08-07 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
CN104531793B (zh) * 2014-12-20 2018-04-27 郁庆明 全细胞生物转化制备l-2-氨基丁酸的方法
SG10202111394XA (en) 2017-04-13 2021-12-30 Senti Biosciences Inc Combinatorial cancer immunotherapy
WO2019016240A1 (en) * 2017-07-19 2019-01-24 Leadiant Biosciences Ltd ADENOSINE DEAMINASE FOR TREATING OR IMPROVING SCLERRODERMIS ASSOCIATED VASCULOPATHY
WO2019155969A1 (ja) * 2018-02-09 2019-08-15 天野エンザイム株式会社 夾雑活性が低減したヌクレオシダーゼ剤
AU2019359890B2 (en) 2018-10-17 2024-10-24 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US20250075196A1 (en) * 2021-11-12 2025-03-06 Georgia Tech Research Corporation Adenosine deaminase 1 compositions and methods for using same
CN116814595B (zh) * 2023-08-30 2023-11-28 江苏申基生物科技有限公司 一种腺苷脱氨酶突变体及其固定化

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1181804A (en) 1913-12-27 1916-05-02 Frank Simpson Removable bottle-valve.
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US5346823A (en) * 1984-05-29 1994-09-13 Genencor, Inc. Subtilisin modifications to enhance oxidative stability
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en) * 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5349001A (en) * 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5321095A (en) * 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
KR100322793B1 (ko) * 1993-02-11 2002-06-20 마가렛 에이.혼 산화안정성알파-아밀라아제
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5650234A (en) * 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5756593A (en) 1995-05-15 1998-05-26 Enzon, Inc. Method of preparing polyalkyene oxide carboxylic acids
US5728560A (en) 1996-06-14 1998-03-17 Enzon, Inc. Method of treating CD4+ T cell lymphopenia in immuno-compromised patients
JP4465109B2 (ja) 1997-12-17 2010-05-19 エンゾン ファーマシューティカルズ，インコーポレーテッド アミノ及びヒドロキシル含有生物活性剤のポリマープロドラッグ
GB2332539B (en) * 1997-12-17 2003-04-23 Fujitsu Ltd Memory access methods and devices for use with random access memories
US6180095B1 (en) * 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6624142B2 (en) * 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US5965119A (en) 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6251382B1 (en) * 1998-04-17 2001-06-26 Enzon, Inc. Biodegradable high molecular weight polymeric linkers and their conjugates
US6824766B2 (en) * 1998-04-17 2004-11-30 Enzon, Inc. Biodegradable high molecular weight polymeric linkers and their conjugates
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6207876B1 (en) * 1998-04-28 2001-03-27 Board Of Regents, The University Of Texas System Adenosine deaminase deficient transgenic mice and methods for the use thereof
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US6366860B1 (en) 2000-01-31 2002-04-02 Biocatalytics, Inc. Synthetic genes for enhanced expression
US7053150B2 (en) * 2000-12-18 2006-05-30 Nektar Therapeutics Al, Corporation Segmented polymers and their conjugates
ES2528384T3 (es) * 2001-12-12 2015-02-09 The Government Of The United States Of America, As Represented By The Secretary Department Of Healt Métodos de utilización de inhibidores del receptor de adenosina para potenciar la respuesta inmunitaria y la inflamación
EP1494706A4 (en) * 2002-03-26 2006-10-25 Biosynexus Inc ANTIMICROBIAL POLYMER CONJUGATES
US7087229B2 (en) * 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7122189B2 (en) * 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7413738B2 (en) * 2002-08-13 2008-08-19 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on biodegradable linkers
CA2511815A1 (en) * 2002-12-26 2004-07-22 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
KR100512483B1 (ko) * 2003-05-07 2005-09-05 선바이오(주) 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
US7301003B2 (en) * 2005-08-26 2007-11-27 Enzon Pharmaceuticals, Inc. Method of preparing polymers having terminal amine groups
US7601798B2 (en) * 2005-10-04 2009-10-13 Enzon Pharmaceuticals, Inc. Methods of preparing polymers having terminal amine groups using protected amine salts
US7989554B2 (en) * 2006-01-10 2011-08-02 Enzon Pharmaceuticals, Inc. Reacting polyalkylene oxide with base, tertiary alkyl haloacetate, then acid to prepare polyalkylene oxide carboxylic acid
CA2653061A1 (en) 2006-06-21 2007-12-27 Enzon Pharmaceuticals, Inc. Stabilized proteins
CN101541332A (zh) 2006-09-15 2009-09-23 安佐制药股份有限公司 含多官能连接基的靶向聚合物前药
KR20090083334A (ko) 2006-09-15 2009-08-03 엔존 파마슈티컬즈, 인코포레이티드 방해된 에스테르 기재 생분해성 링커를 갖는 폴리알킬렌 옥시드
US20080159964A1 (en) * 2006-12-29 2008-07-03 Enzon Pharmaceuticals, Inc. Use of adenosine deaminase for treating pulmonary disease
PL2147122T3 (pl) 2007-04-20 2015-05-29 Leadiant Biosciences Ltd Enzymatyczna terapia przeciwnowotworowa

Also Published As

Publication number Publication date
EP2147116A4 (en) 2010-07-28
IL201592A0 (en) 2010-05-31
JP2010524472A (ja) 2010-07-22
EP2147116A1 (en) 2010-01-27
CN101688244A (zh) 2010-03-31
CA2684750A1 (en) 2008-10-30
CN101688244B (zh) 2013-05-08
SI2147116T1 (sl) 2016-06-30
BRPI0810383A2 (pt) 2019-08-27
TW200902719A (en) 2009-01-16
KR20100016302A (ko) 2010-02-12
CA2684750C (en) 2014-08-05
IL201592A (en) 2016-05-31
NZ580981A (en) 2012-02-24
AU2008242748B2 (en) 2013-12-05
AU2008242748A1 (en) 2008-10-30
HUE027603T2 (en) 2016-10-28
US8071741B2 (en) 2011-12-06
EP2147116B1 (en) 2016-03-02
US20090047271A1 (en) 2009-02-19
JP5511653B2 (ja) 2014-06-04
TWI412591B (zh) 2013-10-21
HK1142639A1 (en) 2010-12-10
HRP20160482T1 (hr) 2016-06-03
WO2008131208A1 (en) 2008-10-30
ES2569940T3 (es) 2016-05-13
RU2009142844A (ru) 2011-05-27
KR101499095B1 (ko) 2015-03-05
BRPI0810383B1 (pt) 2022-12-20
PL2147116T3 (pl) 2016-08-31
DK2147116T3 (en) 2016-05-30

Similar Documents

Publication Publication Date Title
MX2009011319A (es) Adenosina desaminasa recombinante estable.
PH12014502880A1 (en) Lyophilized therapeutic peptibody formulations
MY145117A (en) Disposable diaper
MY146112A (en) Long-term feed - cancer patient
EP1670450B8 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
MX2010005317A (es) Polipeptidos de insulina modificados y sus usos.
MY165570A (en) Inhibitors of poly (adp-ribose) polymerase
SG153800A1 (en) Pharmaceutical compositions
EP2023926A4 (en) PYRIDONECARBOXAMIDE DERIVATIVES USEFUL FOR TREATING HYPERPROLIFERATIVE AND ANGIOGENESIS RELATED DISORDERS
IL200749A0 (en) Modified fgf-21 polypeptides and their uses
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
MX2007011023A (es) 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3.
UA102858C2 (ru) Производные пиридино-пиридинонов, способ их получения и применения в терапии
WO2008066630A3 (en) Methods for reprogramming adult somatic cells and uses thereof
SI1909843T1 (sl) Protitumorski biokonjugati hialuronske kisline ali njenih derivatov, dobljeni z indirektno kemijsko konjugacijo, in njihova uporaba na farmacevtskem področju
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
WO2007061939A3 (en) Metabolite derivatives of the hdac inhibitor fk228
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
TW200715634A (en) Stable organic devices
GEP20115356B (en) Metastin derivatives and use thereof
MX2007005202A (es) Polisacaridos de estreptococo modificados y usos de los mismos.
SG148192A1 (en) Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents
DK2185561T3 (da) Derivater af 1,2,3,4-tetrahydropyrrolo(1,2-a)pyrazin-6-carboxamid og 2,3,4,5-tetrahydroprrolo(1,2-a)-diazepin-7-carboxamid, fremstilling deraf og terapeutisk anvendelse deraf
IN2015DN01788A (es)
MX2008011844A (es) Formulaciones de sitaxsentano de sodio.

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights